NCT00288626View on ClinicalTrials.gov

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
DRUG

Granulocyte-colony stimulating factor (G-CSF) and prednisone

Growth factor regimen; occurs at study entry

DRUG

Carmustine, etoposide, cytarabine, and melphalan (BEAM)

High-dose chemotherapy; occurs seven or more days following collection of autologous graft

PROCEDURE

Autologous hematopoietic stem cell transplant

Occurs after growth factor regimen and collection of autologous graft

Trial Locations (4)

43210

Ohio State University School of Medicine, Columbus

77030

Baylor College of Medicine, Houston

77230-1402

M.D. Anderson Cancer Center; Transplant site, please contact Baylor College of Medicine, Houston

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

Immune Tolerance Network (ITN)

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00288626 - High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study | Biotech Hunter | Biotech Hunter